{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T05:20:13Z","timestamp":1794892813757,"version":"4.9.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T00:00:00Z","timestamp":1689984000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","award":["1R38AI140297"],"award-info":[{"award-number":["1R38AI140297"]}],"id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Surg Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1245\/s10434-023-13935-0","type":"journal-article","created":{"date-parts":[[2023,7,22]],"date-time":"2023-07-22T16:01:38Z","timestamp":1690041698000},"page":"6340-6352","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Timing of Adjuvant Immunotherapy in Stage III Melanoma, Does it Matter?"],"prefix":"10.1245","volume":"30","author":[{"given":"Kristen E.","family":"Rhodin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sin-Ho","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Elleson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"DePalo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Straker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"McKinley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Beekman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lily","family":"Parker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suephy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew K.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April K. S.","family":"Salama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmund","family":"Bartlett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giorgos","family":"Karakousis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan S.","family":"Zager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas S.","family":"Tyler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georgia M.","family":"Beasley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,22]]},"reference":[{"issue":"1","key":"13935_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7\u201330. https:\/\/doi.org\/10.3322\/caac.21590.","journal-title":"CA Cancer J Clin."},{"issue":"6","key":"13935_CR2","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA: A Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA: A Cancer J Clin."},{"issue":"5","key":"13935_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1038\/s41590-022-01141-1","volume":"23","author":"AC Huang","year":"2022","unstructured":"Huang AC, Zappasodi R. A decade of checkpoint blockade immunotherapy in melanoma: understanding the molecular basis for immune sensitivity and resistance. Nat Immunol. 2022;23(5):660\u201370. https:\/\/doi.org\/10.1038\/s41590-022-01141-1.","journal-title":"Nat Immunol."},{"issue":"10304","key":"13935_CR4","doi-asserted-by":"publisher","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","volume":"398","author":"MS Carlino","year":"2021","unstructured":"Carlino MS, Larkin J, Long GV. Immune checkpoint inhibitors in melanoma. The Lancet. 2021;398(10304):1002\u201314. https:\/\/doi.org\/10.1016\/S0140-6736(21)01206-X.","journal-title":"The Lancet."},{"issue":"33","key":"13935_CR5","doi-asserted-by":"publisher","first-page":"3947","DOI":"10.1200\/JCO.20.00198","volume":"38","author":"R Seth","year":"2020","unstructured":"Seth R, Messersmith H, Kaur V, et al. Systemic therapy for melanoma: ASCO guideline. J Clin Oncol. 2020;38(33):3947\u201370. https:\/\/doi.org\/10.1200\/JCO.20.00198.","journal-title":"J Clin Oncol."},{"issue":"19","key":"13935_CR6","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont AMM, Blank CU, Mandala M, et al. Adjuvant Pembrolizumab versus Placebo in resected stage III melanoma. New Engl J Med. 2018;378(19):1789\u2013801. https:\/\/doi.org\/10.1056\/NEJMoa1802357.","journal-title":"New Engl J Med."},{"issue":"19","key":"13935_CR7","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1056\/NEJMoa1611299","volume":"375","author":"AMM Eggermont","year":"2016","unstructured":"Eggermont AMM, Chiarion-Sileni V, Grob J-J, et al. Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New Engl J Med. 2016;375(19):1845\u201355. https:\/\/doi.org\/10.1056\/NEJMoa1611299.","journal-title":"New Engl J Med."},{"issue":"19","key":"13935_CR8","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","volume":"377","author":"J Weber","year":"2017","unstructured":"Weber J, Mandala M, Del Vecchio M, et al. Adjuvant Nivolumab versus Ipilimumab in resected stage III or IV melanoma. New Engl J Med. 2017;377(19):1824\u201335. https:\/\/doi.org\/10.1056\/NEJMoa1709030.","journal-title":"New Engl J Med."},{"key":"13935_CR9","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Melanoma Cutaneous. Updated April 11, 2022. Accessed 31 August 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cutaneous_melanoma.pdf."},{"issue":"10336","key":"13935_CR10","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/s0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke JJ, Rutkowski P, Queirolo P, et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet (London, England). 2022;399(10336):1718\u201329. https:\/\/doi.org\/10.1016\/s0140-6736(22)00562-1.","journal-title":"Lancet (London, England)."},{"key":"13935_CR11","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon Cancer. Accessed 31 August 2022. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/colon.pdf."},{"issue":"4","key":"13935_CR12","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.jamcollsurg.2017.12.048","volume":"226","author":"MC Turner","year":"2018","unstructured":"Turner MC, Farrow NE, Rhodin KE, et al. Delay in adjuvant chemotherapy and survival advantage in stage III colon cancer. J Am Coll Surg. 2018;226(4):670\u20138. https:\/\/doi.org\/10.1016\/j.jamcollsurg.2017.12.048.","journal-title":"J Am Coll Surg."},{"issue":"22","key":"13935_CR13","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1001\/jama.2011.749","volume":"305","author":"JJ Biagi","year":"2011","unstructured":"Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA. 2011;305(22):2335\u201342. https:\/\/doi.org\/10.1001\/jama.2011.749.","journal-title":"JAMA."},{"issue":"5","key":"13935_CR14","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1001\/jamaoncol.2016.5829","volume":"3","author":"MC Salazar","year":"2017","unstructured":"Salazar MC, Rosen JE, Wang Z, et al. Association of delayed adjuvant chemotherapy with survival after lung cancer surgery. JAMA Oncol. 2017;3(5):610\u20139. https:\/\/doi.org\/10.1001\/jamaoncol.2016.5829.","journal-title":"JAMA Oncol."},{"issue":"3","key":"13935_CR15","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1016\/j.athoracsur.2020.03.040","volume":"110","author":"KE Rhodin","year":"2020","unstructured":"Rhodin KE, Raman V, Jawitz OK, Tong BC, Harpole DH, D\u2019Amico TA. The effect of timing of adjuvant therapy on survival after esophagectomy. Ann Thorac Surg. 2020;110(3):1023\u20139. https:\/\/doi.org\/10.1016\/j.athoracsur.2020.03.040.","journal-title":"Ann Thorac Surg."},{"issue":"1","key":"13935_CR16","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s40425-018-0398-7","volume":"6","author":"O Bakos","year":"2018","unstructured":"Bakos O, Lawson C, Rouleau S, Tai L-H. Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity. J ImmunoTherapy Cancer. 2018;6(1):86. https:\/\/doi.org\/10.1186\/s40425-018-0398-7.","journal-title":"J ImmunoTherapy Cancer."},{"issue":"6","key":"13935_CR17","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1016\/S1470-2045(16)00141-8","volume":"17","author":"U Leiter","year":"2016","unstructured":"Leiter U, Stadler R, Mauch C, et al. Complete lymph node dissection versus no dissection in patients with sentinel lymph node biopsy positive melanoma (DeCOG-SLT): a multicentre, randomised, phase 3 trial. Lancet Oncol. 2016;17(6):757\u201367. https:\/\/doi.org\/10.1016\/S1470-2045(16)00141-8.","journal-title":"Lancet Oncol."},{"issue":"23","key":"13935_CR18","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa1613210","volume":"376","author":"MB Faries","year":"2017","unstructured":"Faries MB, Thompson JF, Cochran AJ, et al. Completion Dissection or observation for sentinel-node metastasis in melanoma. New Engl J Med. 2017;376(23):2211\u201322. https:\/\/doi.org\/10.1056\/NEJMoa1613210.","journal-title":"New Engl J Med."},{"issue":"3","key":"13935_CR19","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1161\/circoutcomes.110.957951","volume":"4","author":"U Dafni","year":"2011","unstructured":"Dafni U. Landmark analysis at the 25-year landmark point. Circ Cardiovasc Qual Outcomes. 2011;4(3):363\u201371. https:\/\/doi.org\/10.1161\/circoutcomes.110.957951.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"issue":"23","key":"13935_CR20","doi-asserted-by":"publisher","first-page":"2963","DOI":"10.1200\/jco.2013.49.5283","volume":"31","author":"A Giobbie-Hurder","year":"2013","unstructured":"Giobbie-Hurder A, Gelber RD, Regan MM. Challenges of guarantee-time bias. J Clin Oncol. 2013;31(23):2963\u20139. https:\/\/doi.org\/10.1200\/jco.2013.49.5283.","journal-title":"J Clin Oncol."},{"issue":"8","key":"13935_CR21","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1002\/jso.21173","volume":"99","author":"MV Raval","year":"2009","unstructured":"Raval MV, Bilimoria KY, Stewart AK, Bentrem DJ, Ko CY. Using the NCDB for cancer care improvement: an introduction to available quality assessment tools. J Surg Oncol. 2009;99(8):488\u201390. https:\/\/doi.org\/10.1002\/jso.21173.","journal-title":"J Surg Oncol."},{"issue":"12","key":"13935_CR22","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1001\/jamaoncol.2016.6905","volume":"3","author":"DJ Boffa","year":"2017","unstructured":"Boffa DJ, Rosen JE, Mallin K, et al. Using the national cancer database for outcomes research\u2014a review. JAMA Oncol. 2017;3(12):1722\u20138. https:\/\/doi.org\/10.1001\/jamaoncol.2016.6905.","journal-title":"JAMA Oncol."},{"issue":"34_suppl","key":"13935_CR23","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/jco.2012.30.34_suppl.173","volume":"30","author":"AB Haynes","year":"2012","unstructured":"Haynes AB, Chiang YS, Boland GM. Socioeconomic and clinical factors associated with delayed initiation of adjuvant chemotherapy for stage III colon cancer. J Clin Oncol. 2012;30(34_suppl):173\u2013173. https:\/\/doi.org\/10.1200\/jco.2012.30.34_suppl.173.","journal-title":"J Clin Oncol."},{"issue":"1","key":"13935_CR24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.ygyno.2021.04.032","volume":"162","author":"S Cham","year":"2021","unstructured":"Cham S, Huang Y, Melamed A, et al. Fragmentation of surgery and chemotherapy in the initial phase of ovarian cancer care and its association with overall survival. Gynecol Oncol. 2021;162(1):56\u201364. https:\/\/doi.org\/10.1016\/j.ygyno.2021.04.032.","journal-title":"Gynecol Oncol."},{"issue":"1","key":"13935_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/ctm2.24","volume":"10","author":"F Tang","year":"2020","unstructured":"Tang F, Tie Y, Tu C, Wei X. Surgical trauma-induced immunosuppression in cancer: recent advances and the potential therapies. Clin Transl Med. 2020;10(1):199\u2013223. https:\/\/doi.org\/10.1002\/ctm2.24.","journal-title":"Clin Transl Med."},{"issue":"11","key":"13935_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.it.2020.09.003","volume":"41","author":"M Hill","year":"2020","unstructured":"Hill M, Segovia M, Russo S, Girotti MR, Rabinovich GA. The paradoxical roles of inflammation during PD-1 blockade in cancer. Trends Immunol. 2020;41(11):982\u201393. https:\/\/doi.org\/10.1016\/j.it.2020.09.003.","journal-title":"Trends Immunol."},{"issue":"3","key":"13935_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1038\/s41590-019-0312-6","volume":"20","author":"BC Miller","year":"2019","unstructured":"Miller BC, Sen DR, Al Abosy R, et al. Subsets of exhausted CD8(+) T cells differentially mediate tumor control and respond to checkpoint blockade. Nat Immunol. 2019;20(3):326\u201336. https:\/\/doi.org\/10.1038\/s41590-019-0312-6.","journal-title":"Nat Immunol."},{"issue":"13","key":"13935_CR28","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1056\/NEJMoa2032125","volume":"384","author":"RJ Kelly","year":"2021","unstructured":"Kelly RJ, Ajani JA, Kuzdzal J, et al. Adjuvant nivolumab in resected esophageal or gastroesophageal junction cancer. New Engl J Med. 2021;384(13):1191\u2013203. https:\/\/doi.org\/10.1056\/NEJMoa2032125.","journal-title":"New Engl J Med."},{"key":"13935_CR29","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1056\/NEJMoa2211437","volume":"388","author":"S Patel","year":"2023","unstructured":"Patel S, Othus M, Chen Y, et al. Neoadjuvant-adjuvant or adjuvant-only pembrolizumab in advanced melanoma. New Engl J Med. 2023;388:813\u201323. https:\/\/doi.org\/10.1056\/NEJMoa2211437.","journal-title":"New Engl J Med."},{"key":"13935_CR30","doi-asserted-by":"publisher","unstructured":"Sarver M, Brown MC, Rhodin KE, Salama AKS, Beasley GM. Predictive factors of neoadjuvant immune checkpoint blockade in melanoma. Hum Vaccin Immunother. 2022;18(3):1943987. doi:https:\/\/doi.org\/10.1080\/21645515.2021.1943987","DOI":"10.1080\/21645515.2021.1943987"},{"issue":"11","key":"13935_CR31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1038\/s41591-018-0250-0","volume":"24","author":"C Robert","year":"2018","unstructured":"Robert C. Is earlier better for melanoma checkpoint blockade? Nat Med. 2018;24(11):1645\u20138. https:\/\/doi.org\/10.1038\/s41591-018-0250-0.","journal-title":"Nat Med."}],"container-title":["Annals of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13935-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1245\/s10434-023-13935-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1245\/s10434-023-13935-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,18]],"date-time":"2023-09-18T14:08:12Z","timestamp":1695046092000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1245\/s10434-023-13935-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,22]]},"references-count":31,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["13935"],"URL":"https:\/\/doi.org\/10.1245\/s10434-023-13935-0","relation":{},"ISSN":["1068-9265","1534-4681"],"issn-type":[{"value":"1068-9265","type":"print"},{"value":"1534-4681","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,22]]},"assertion":[{"value":"14 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Rhodin is supported by NIH 1R38AI140297. G. Beasley has received clinical trial funding paid to Duke University from Delcath, Istari, Replimune, Oncosec, and Checkmate. G. Beasley has been a one-time member of the advisory board for Cardinal Health and Regeneron. G. Beasley is supported by NIH K08 CA237726-01A1. A. Salama discloses Research Funding (paid to institution): Ascentage, BMS, Ideaya, Immunocore, Merck, Olatec Therapeutics, Pfizer, Regeneron Pharmaceuticals, Replimune, and Seattle Genetics; Advisory Boards: BMS, Iovance Biotherapeutics, Novartis, Pfizer, Regeneron Pharmaceuticals, and Replimune. E. Bartlett discloses institutional research funding from Skyline Dx and honorarium from Excite International. G. Karakousis discloses institutional research support from and advisory board work for Merck. J. Zager has done advisory board work for Merck.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosure"}}]}}